Muscat: The National Diabetes and Endocrine Centre at the Royal Hospital, has introduced the unique drug Vosoritide (Foxzogo) for treating children with Achondroplasia (the most common cause of dwarfism in children).
The move makes the Royal Hospital one of the first leading centres in the region to provide this advanced treatment.
This drug represents a qualitative leap in the care of children with this type of dwarfism, as it targets overactive pathways that hinder normal bone growth thus stimulating bone growth in children whose growth plates are still open.
The centre explained that the treatment continues until the bones are fully developed and the growth cartilage close, stressing the importance of undelayed use of the drug to ensure that treatment is initiated at the optimal time in order to achieve the best possible results.
Oman Observer is now on the WhatsApp channel. Click here
